Curasight A/S
Ulrich Krasilnikoff is an experienced executive currently serving as CEO and CFO of Curasight, a biotech company specialized in cancer diagnosis and treatment through its innovative imaging ligand, uTRACE®. In addition to this role, Krasilnikoff holds various positions including lay judge at Danmarks Domstole, co-owner and board member at Primodan A/S, and chairman of the board at Krasilnikoff A/S, which achieved notable growth as a Gazelle company. Previous roles include CFO and Executive Vice President at BIOFAC Group, board member positions at CARL HANSEN & SØN and AH METAL SOLUTIONS A/S, and associate partner roles at Capidea and Business Broker A/S. Education includes a Master of Business Administration from the University of Southern Denmark and degrees in engineering and business from DTU and Copenhagen Business School, respectively.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.